BACKGROUND: Differentiating @entity1 with @entity1368 caused by @entity1369 -producing adenomas (APAs) from those with @entity774 ( @entity774 ), which is essential for choice of therapeutic intervention, relies on @entity1211 ( @entity1211 )-based measurements of @entity1369 and @entity701 . We assessed the utility of LC- @entity15 / @entity15 -based @entity479 profiling to stratify @entity1 with @entity1368 . METHODS: Fifteen adrenal @entity230 were measured by LC- @entity15 / @entity15 in peripheral and adrenal venous plasma from @entity1211 studies for 216 @entity1 with @entity1368 at 3 tertiary referral centers. Ninety @entity1 were diagnosed with @entity774 and 126 with APAs on the basis of immunoassay-derived adrenal venous @entity1369 lateralization ratios. RESULTS: Among 119 @entity1 confirmed to have APAs at follow-up, LC- @entity15 / @entity15 -derived lateralization ratios of @entity1369 normalized to @entity701 , @entity2494 , and @entity2671 were all higher (P < 0.0001) than immunoassay-derived ratios. The hybrid @entity230 , @entity49227 and @entity13232 , also showed lateralized secretion in 76% and 35% of @entity1 with APAs. Adrenal venous concentrations of glucocorticoids and @entity3800 were bilaterally higher in @entity1 with @entity774 than in those with APAs. Consequently, peripheral plasma concentrations of @entity49227 were 8.5-fold higher, whereas concentrations of @entity701 , @entity2819 , and @entity2494 were lower in @entity1 with APAs than in those with @entity774 . Correct classification of 80% of cases of APAs vs @entity774 was thereby possible by use of a combination of @entity230 in peripheral plasma. CONCLUSIONS: LC- @entity15 / @entity15 -based @entity479 profiling during @entity1211 achieves higher @entity1369 lateralization ratios in @entity1 with APAs than immunoassay. LC- @entity15 / @entity15 also enables multiple measures for discriminating unilateral from bilateral @entity1369 excess, with potential use of peripheral plasma for subtype classification.

Mass Spectrometry-Based Adrenal and Peripheral Venous XXXX Profiling for Subtyping Primary Aldosteronism.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone'] @entity2494 :: ('MESH:D003687', 'Chemical') :: ['dehydroepiandrosterone'] @entity2671 :: ('MESH:D000735', 'Chemical') :: ['androstenedione'] @entity13232 :: ('MESH:C033689', 'Chemical') :: ['18-hydroxycortisol'] @entity3800 :: ('MESH:D000728', 'Chemical') :: ['androgens'] @entity2819 :: ('MESH:D003345', 'Chemical') :: ['corticosterone'] @entity49227 :: ('MESH:C038135', 'Chemical') :: ['18-oxocortisol'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol'] @entity479 :: ('D013256', 'Chemical') :: ['steroid'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['AVS', 'adrenal venous sampling'] @entity15 :: ('MESH:D009103', 'Disease') :: ['MS'] @entity1368 :: ('MESH:D006929', 'Disease') :: ['primary aldosteronism'] @entity774 :: ('MESH:D000312', 'Disease') :: ['BAH', 'bilateral adrenal hyperplasia']
@entity479 :: (D013256,Chemical) :: ['Steroid']
